NCT03250832 - Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

June 2, 2022

Study Completion Date

February 13, 2023

Conditions

Neoplasms

Interventions

DRUG

TSR-033

TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.

DRUG

Dostarlimab

Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.

DRUG

mFOLFOX6

mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.

DRUG

FOLFIRI

FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.

DRUG

Bevacizumab

Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.

Trial Locations (12)

15232

GSK Investigational Site, Pittsburgh

29605

GSK Investigational Site, Greenville

33612

GSK Investigational Site, Tampa

34232

GSK Investigational Site, Sarasota

44106

GSK Investigational Site, Cleveland

73104

GSK Investigational Site, Oklahoma City

77030

GSK Investigational Site, Houston

78229

GSK Investigational Site, San Antonio

90095

GSK Investigational Site, Los Angeles

90603

GSK Investigational Site, Whittier

94805

GSK Investigational Site, Villejuif

02115

GSK Investigational Site, Boston